David Jonathan Gottlieb

David Jonathan Gottlieb

Auto-generated profile, based on publicly available information

David Jonathan Gottlieb

Faculty of Medicine and Health The University of Sydney Camperdown New South Wales Australia

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2013 in Blood
Verified
Journal Article
Closed access
PDF file
EBEmily Blyth
Emily Blyth
LCLeighton Clancy
Leighton Clancy
RSRenee Simms
Renee Simms
CMChun K. K. Ma
Chun K. K. Ma
JBJane Burgess
Jane Burgess
DGDavid J. Gottlieb
David J. Gottlieb
We investigated the use of adoptively transferred donor-derived cytomegalovirus (CMV) specific cytotoxic T lymphocytes (CTL) as immune reconstitution postallogeneic transplant in a phase 2 study. Fifty patients were infused with a single dose of 2 × 107cells/m2 after day 28 post-transplant. Twenty-six patients reactivated CMV posttransplant (only 5 post-CTL infusion) and 9 required therapy with ganciclovir or foscarnet (only 1 post-CTL infusion). There was 1 case of fatal CMV disease, attributable to high levels of antithymocyte globulin at the time of T cell infusion. We compared the patients in the phase 2 study with a group of contemporaneous controls also treated at the trial centers. There was no increase in acute or chronic graft-versus-host disease attributable to CTL infusion; overall and progression-free survival were similar in both groups. There was a reduction in the percentage of patients who required CMV directed antiviral therapy (17% vs 36%, P = .01) and in the total number of treatment days in the cohort receiving CTL (3.4 days vs 8.9 days, P = .03) without a reduction in CMV reactivation rates. We postulate that adoptively transferred cells are able to expand in response to viral antigen, limit viral replication, and prevent progression to tissue infection. This study was registered on the Australian Clinical Trial Registry as #ACTRN12605000213640 and #ACTRN12607000224426.

20 June 2003 in Leukemia
Verified
Journal Article
Closed access
JJJ Juarez
J Juarez
KBK F Bradstock
K F Bradstock
DGD J Gottlieb
D J Gottlieb
LBL J Bendall
L J Bendall

20 August 2010 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
BGB. George
B. George
NPN. Pati
N. Pati
NGN. Gilroy
N. Gilroy
MRM. Ratnamohan
M. Ratnamohan
GHG. Huang
G. Huang
KBK. Bradstock
K. Bradstock

2 November 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
BWBarbara Withers
Barbara Withers
EBEmily Blyth
Emily Blyth
LCLeighton E. Clancy
Leighton E. Clancy
AYAgnes Yong
Agnes Yong
CFChris Fraser
Chris Fraser
DGDavid J. Gottlieb
David J. Gottlieb
Key Points: Partially HLA-matched third-party CMV-specific T cells provide long-term viral control in HSCT patients with resistant CMV infection. Viral control occurs in the setting of recovery of CD8+ terminally differentiated effector T cells.

21 January 2009 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
GBGary Brooke
Gary Brooke
TRTony Rossetti
Tony Rossetti
RPRebecca Pelekanos
Rebecca Pelekanos
NINina Ilic
Nina Ilic
PMPatricia Murray
Patricia Murray
KAKerry Atkinson
Kerry Atkinson

1 June 2007 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
KMKenneth Micklethwaite
Kenneth Micklethwaite
AHAnna Hansen
Anna Hansen
AFAaron Foster
Aaron Foster
ESElizabeth Snape
Elizabeth Snape
VAVicki Antonenas
Vicki Antonenas
DGDavid Gottlieb
David Gottlieb
Cytomegalovirus reactivation and infection post-allogeneic hematopoietic stem cell transplant continue to cause morbidity and mortality. Current pharmacologic therapies are limited by side effects. Adoptive transfer of ex vivo generated cytomegalovirus-specific T cells has the potential to restore immunity, prevent cytomegalovirus, and circumvent the need for pharmacologic therapies. We have generated donor-derived cytomegalovirus-specific cytotoxic T cells using dendritic cells pulsed with the HLA-A2 restricted nonapeptide NLVPMVATV (NLV) derived from the cytomegalovirus-pp65 protein. These cytotoxic T cells have been given prophylactically to 9 recipients aged 4 to 65 years on or after day 28 post-allogeneic hematopoietic stem cell transplant. Only 2 of 9 recipients received T cell depletion in vivo or in vitro. There were no immediate adverse reactions to the infusions. During 97-798 days of follow-up, 2 recipients developed cytomegalovirus reactivation; neither developed cytomegalovirus disease or required pharmacotherapy. Three recipients developed acute graft versus host disease after infusion. Two recipients died, 1 from thrombotic thrombocytopenia purpura secondary to cyclosporine, 1 from complications of graft versus host disease. A transient increase in numbers of cytomegalovirus-specific T cells demonstrated by NLV-tetramer binding was seen in 6 recipients. Prophylactic adoptive transfer of NLV-specific T cells is safe and may be effective in preventing cytomegalovirus reactivation.